Related Experiment Video
Updated: Aug 9, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Tirofiban
1Department of Medicine, Montreal Heart Institute and University of Montreal, Québec, Canada.
Abstract:
Tirofiban is an antagonist of the gpIIb/IIIa receptor. It was developed as an intravenous agent for rapid, potent and reversible inhibition of platelet aggregation. It produces dose-related inhibition of aggregation. Its efficacy has been demonstrated in disease states associated with intravascular thrombus formation, such as occurs with unstable angina pectoris, non-Q-wave myocardial infarction and during percutaneous coronary interventions. This review describes the pharmacokinetics and pharmacodynamics of tirofiban in normal volunteers and in patients with coronary artery disease, including patients with renal or hepatic insufficiency, as well as the results of the phase III program that has studied the efficacy and safety profile of the drug. Modalities for its clinical use are also discussed.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Venous Thrombosis III: Interprofessional Care

